AbbVie Inc. (ABBV)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for ABBV is $281.54, 1.4% below the last close of $285.42 on Oct 16, 2026; targets range from $217.17 to $319.82. Rating consensus: Buy.
Snapshot
- P/E80.4x
- P/E vs sector+185.6%
- P/E vs own-28.2%
- Target upside-1.4%
- ConsensusBuy
- Market cap$504B
- FCF yield+3.6%
- Insiders-$8.18M
- Earnings in14d
- News
Why it moved
AbbVie Inc. (ABBV) rose 0.7% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move is specific to ABBV.
4 stories on the day (30-day average 3.8).
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- AbbVie Inc. $ABBV Shares Sold by Banque Pictet & Cie SA
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $285.42 · +29.6% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50—
- RSI72
- Support-7.3%
- Resistance—
- Off 52w high0.0%
- Off ATH0.0%
- 52w range$285.42
- Bollingerabove upper
- MACD1.85
- ATR+2.3%
- Volume1.2x
Analyst price targets
17 firms with a target in the last 12 months · last close $285.42 · as of Oct 16, 2026
Strong buy 8 · Buy 16 · Hold 5 · Sell 0 · Strong sell 1
Revenue and free cash flow
Q2 FY2026: Revenue +10.2% year over year, free cash flow 18.3% of revenue, operating margin 37.9%.
| Q2 FY2026 | Jun 30, 2026 | $16.99B | 2.04 | $3.11B | 74.7% | 37.9% | 21.3% |
| Q1 FY2026 | Mar 31, 2026 | $15B | 0.39 | $3.56B | 71.9% | 31.6% | 4.7% |
| Q4 FY2025 | Dec 31, 2025 | $16.62B | 1.02 | $4.89B | 72.6% | 35.0% | 10.9% |
| Q3 FY2025 | Sep 30, 2025 | $15.78B | 0.10 | $6.64B | 66.4% | 12.1% | 1.2% |
| Q2 FY2025 | Jun 30, 2025 | $15.42B | 0.53 | $4.88B | 71.8% | 31.7% | 6.1% |
| Q1 FY2025 | Mar 31, 2025 | $13.34B | 0.72 | $1.4B | 70.0% | 28.0% | 9.6% |
| Q4 FY2024 | Dec 31, 2024 | $15.1B | -0.02 | $6.76B | 70.9% | -9.9% | -0.1% |
| Q3 FY2024 | Sep 30, 2024 | $14.46B | 0.88 | $5.2B | 70.9% | 26.5% | 10.8% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $1,257.03 | +0.4% | -1.8% | +4.5% | 42.2 | $1.18T | |
| 2 |  | $255.56 | +0.9% | -8.2% | +8.8% | 38.7 | $616B | |
| 3 | | $285.42 | +0.7% | 0.0% | -1.4% | 80.4 | $504B | |
| 4 |  | $145.95 | +0.5% | -6.2% | +7.7% | 116.8 | $360B | |
| 5 |  | $432.49 | -0.4% | -2.6% | -7.5% | 26.9 | $234B | |
| 6 |  | $156.19 | -0.7% | -0.7% | +1.9% | — | $194B | |
| 7 |  | $29.58 | +0.5% | 0.0% | -7.1% | 39.1 | $169B | |
| 8 |  | $59.75 | -1.4% | -11.3% | +9.4% | 13.2 | $122B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.